For the preventive treatment of migraine in adults^1-3

Why add to your patients' pill burden?

For migraine prevention, once-monthly injectable Emgality doesn't require your patients to adhere to a daily or every-other-day oral gepant dosing schedule^1-3

Doses per year^1-3

Visual showing doses per year for Emgality (galcanezumab-gnlm), Nurtec ODT (rimegepant), and Qulipta (atogepant) — Doses during one year of therapy^1-3:

Emgality (galcanezumab-gnlm) is 12 doses a year (1 injection every month)^a

Nurtec ODT (rimegepant) is 182 doses a year (1 pill every other day)

Qulipta (atogepant) is 365 doses a year (1 pill every day)

Patients on some oral preventive treatments may be taking up to 365 doses per year. Emgality is 12 doses per year.^1-3a

Pill burden is defined by the total number of pills a patient takes on a daily or regular basis.^4,5

^aAfter an initial loading dose of 240 mg (2 x 120 mg injections).¹

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

References

Emgality. Prescribing Information. Lilly USA, LLC.
Nurtec ODT. Prescribing Information. Pfizer Ireland Pharmaceuticals, Inc.
Qulipta. Prescribing Information. AbbVie Inc.
Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-1096.
Pill burden definition. National Institutes of Public Health. Clinicalinfo.HIV.gov glossary. Accessed May 20, 2022. https://clinicalinfo.hiv.gov/en/glossary/pill-burden.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

Preventive treatment of migraine
Treatment of episodic cluster headache